AAA today announced its financial results for the first quarter of 2016. Commenting on the first quarter performance, Stefano Buono, AAA’s CEO, said, “Our continued sales momentum provides a strong foundation for the commercial launches of both Somakit and Lutathera, as well as the expansion of our theragnostic franchise as a whole.” Mr. Buono continued, “We are committed to continuing to deliver improved outcomes for patients with unmet medical needs through our specialized expertise in the development and production of molecular nuclear medicines, and the accomplishments of this past quarter underscore the progress we are making to that end.”
First Quarter Highlights:
– Sales for the first quarter of 2016 increased 29.6% compared to the first quarter of 2015
– Purchased 100% of the IDB Group to strengthen AAA’s commercial positioning of Lutathera
– Entered into a non-exclusive agreement with Zevacor for the preparation and delivery of SomaKit-TATE in the US
– Signed an exclusive licensing agreement with Johns Hopkins University to develop and market PSMA receptor ligand in prostate cancer for clinical therapeutic and diagnostic purposes